FDA Approves Bictegravir-Lenacapavir Combo Pill for Virally Suppressed HIV

New Treatment Option for Suppressed HIV Patients

The newly approved medication contains 75 mg of bictegravir, an integrase strand transfer inhibitor, and 50 mg of lenacapavir, a capsid inhibitor. It is specifically indicated for adults with HIV-1 RNA levels below 50 copies/mL and no resistance to either active compound.

According to Dr. Chloe Orkin from Queen Mary University of London, this approval represents a significant advancement in HIV therapy, particularly for individuals who cannot use standard single-tablet regimens due to pre-existing resistance issues or adverse effects.

Clinical Trial Results Support Approval

The FDA's decision was based on data from two phase III clinical trials: ARTISTRY-1 and ARTISTRY-2. In the first study involving 557 virally suppressed patients on complex oral regimens, only 0.8% of those who switched to the new formulation showed detectable HIV-1 levels at 48 weeks, compared to 1.1% in the control group continuing previous treatment.

No resistance mutations emerged against either active compound in either treatment group. Adverse event rates remained comparable between all study arms, including serious events.

Second Study Confirms Efficacy

In ARTISTRY-2, the bictegravir-lenacapavir combination was directly compared against the standard regimen of bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy). After 48 weeks, 1.3% of patients in the combination group had detectable virus versus 1.0% in the Biktarvy group.

Dosing and Administration Guidelines

Treatment-emergent adverse events occurred at equivalent rates between both study groups, with no treatment-related serious adverse events reported.

The approved dosing schedule requires a two-day initiation phase. Patients take one bictegravir-lenacapavir tablet alongside two 300 mg lenacapavir tablets (Sunlenca) daily. This is followed by maintenance dosing with a single bictegravir-lenacapavir tablet each day.

Side Effects and Future Research

The medication can be taken with or without food. However, the prescribing information contraindicates concurrent use with dofetilide, strong CYP3A inducers, or other antiretroviral therapies for HIV-1.

The most commonly reported adverse reactions include headache, nausea, and diarrhea. Additional clinical trials are currently underway evaluating oral lenacapavir in other combinations for virally suppressed HIV patients, including a protocol combining lenacapavir with islatravir against conventional backbone regimens.